top of page

SBIR award

Ibex announces SBIR award

Ibex Biosciences will continue to develop anti-MIF VHH antibodies by establishing larger production levels of the VHH and testing them in animal models. Our work will start with construction and expression of anti-MIF VHH and VHH-Fc antibodies. Successful feasibility work will focus on their characterization and demonstration of their functional antibody binding in cell lines and animal models. While MIF has been demonstrated to play significant roles in many oncologic conditions, this evaluation will focus on prostate cancer for an initial proof of concept. Subsequent development efforts will expand to other solid tumor cancers as well as inflammatory diseases. http://grantome.com/grant/NIH/R43-CA224732-01

Copyright © 2017-2025 Ibex Biosciences, Inc.

bottom of page